Biotech Market Challenges and Strategies in UAE's Gulf Region

Role: marketing

Industry: Biotech in gulf countries

Situation:

Organizational Situation – Company Product (UAE ) 1. Organizational Attributes The organization operates as a regional affiliate of a global biotechnology company, with a strong presence across GCC markets. It follows a matrix structure with cross-functional teams across Medical Affairs, Market Access, Commercial, and Regulatory functions. Strategy is aligned globally, while execution is locally driven. The organization has a strong scientific and compliance-driven culture, with high credibility among specialists and a focus on evidence-based engagement. ⸻ 2. Primary Challenges and Constraints • Ongoing loss of market share (2–4% annually) despite strong double-digit growth (~35%) of the company product • Increased competitive pressure following the launch of a competitor product in 2022 • Historical narrow positioning (post-acute / high-risk setting) dyslipidemia limiting broader adoption of the company product • Limited expansion into primary prevention and broader high-risk populations despite label flexibility • Gaps in patient identification, particularly in diabetic high-risk populations • Complexity in cardiovascular risk assessment tools, which are not fully adapted to local populations and may not resonate with physicians • Limited activation beyond specialist segments in earlier phases • Less developed patient support programs, particularly around injectable adherence ⸻ 3. Competitive and Market Situation The lipid management landscape in the UAE has evolved significantly following the launch of a competitor product in 2022, which has rapidly become the market leader with approximately 55% market share, compared to ~35% for the company product, while other competitors have minimal active promotion. While the company product continues to grow at a strong rate, it is consistently losing incremental share to the competitor product. Key differentiating factors driving competitor success include: • Broad and early access across the full dyslipidemia spectrum, including primary and secondary prevention • Early and extensive engagement across multiple specialties, including: • Cardiologists (including cath lab) • Endocrinologists • Internists • Expansion beyond traditional specialist segments, building early brand loyalty across a wider prescriber base • Strong positioning around: • Adherence (infrequent dosing schedule) • Simplicity and practicality • Equivalent clinical efficacy with easier implementation The competitor's messaging is perceived as: • Simple • Practical • Aligned with the realities of busy clinical practice In contrast, current positioning is more focused on: • Early and intesne LDL-c reduction • Cardiovascular risk stratification which may be perceived as more complex and less actionable in daily practice. ⸻ 4. Organization's Strengths and Weaknesses Strengths • Strong clinical efficacy and robust evidence base • Established presence and credibility with key opinion leaders • First-mover advantage in the therapeutic class • Continued strong growth despite competitive pressure • Increasing investment in real-world evidence to strengthen positioning Weaknesses • Narrow historical positioning (acute / high-risk focus) • Slower expansion into broader patient segments compared to competitors • Limited engagement with non-traditional prescribers (e.g., internists, endocrinologists) in earlier phases • Messaging perceived as more complex vs competitor's simpler value proposition • Less developed patient support programs focused on adherence and injection management • Lag in real-world evidence generation compared to competitor (currently being addressed) • Lower field force allocation in Medical and Market Access compared to competitor ⸻ 5. Customer Profile and Demographics Healthcare Professionals • Cardiologists (primary prescribers, including interventional specialists) • Endocrinologists (increasingly important due to diabetic population) • Internists (critical for scale and broader patient identification) Payers and Health Authorities • Private insurance providers • Government health systems • Hospital formulary and procurement committees Patients • Predominantly high and very high cardiovascular risk patients, especially: • Diabetic patients • Secondary prevention populations • Significant unmet need in early identification and treatment optimization

Question to Marcus:

“

Which framework(s)/templates are the most suitable for a recovery market starget plan

Marketing Strategy

In the UAE/GCC context, the recovery market strategy must pivot from purely scientific positioning to a pragmatic, practice-oriented marketing approach that meets busy clinicians’ needs. Reframe messaging to emphasize simplicity, implementation ease, and patient outcomes (adherence, reduced visits, predictable LDL-c control) while retaining the robust efficacy data for specialists.

Create tailored value narratives for three priority audiences—cardiology (including cath lab), endocrinology, and internists—each with concrete clinical workflows showing when and how to initiate therapy, titrate, and monitor. Integrate market access and medical affairs early so marketing claims align with formulary/payer criteria and local guideline adoption. Invest in field segmentation and redeploy a higher share of field force to non-traditional prescribers and high-volume hospitals/clinics; support with concise clinical decision aids, one-page protocols, and peer-led local case rounds. Use a phased rollout: defend core specialist accounts with evidence-driven excellence while concurrently driving share expansion via simple, practical messages to broader prescribers and payers. Track KPIs beyond prescriptions—patient initiation rates, persistence at 3/6/12 months, formulary wins, and share within target segments—and use rapid-cycle marketing experiments (A/B messaging, channel mix) to refine what resonates locally. Ensure all activity is culturally adapted (Arabic/English materials) and compliant with local regulations and payer documentation requirements.

Product Go-to-Market Strategy

Define a targeted go-to-market that expands beyond the historical acute/high-risk footprint into primary prevention and broader high-risk cohorts without overextending resources. Start with a focused “beachhead” approach: select high-volume hospitals and integrated clinics with mixed cardiology/endocrinology caseloads in Dubai and Abu Dhabi, plus major private insurers that influence national pathways.

Create integrated launch bundles for each site: a hospital formulary dossier focused on local budget impact and adherence gains, a streamlined patient identification pathway embedded into diabetes and cardiology clinics, and joint medico-commercial HCP education sessions. Align pricing and reimbursement tactics with local payer levers (e.g., outcomes-based agreements, volume discounts, multi-year contracts) and prepare tender-ready documentation for public hospitals. Operationalize a cross-functional playbook—field, medical, market access, and regulatory—with clear responsibilities, timelines, and decision gates for expansion to new segments. Use digital tools (CRM, remote detailing, e-learning) to amplify reach with limited field force and to monitor initiation/adherence. Prioritize tactical wins that shift prescribing behavior (e.g., cath lab protocols, endocrinology co-management) and codify successful site models as replicable templates for rapid scale across the GCC.

Targeting

Refine targeting to prioritize clinics, prescribers, and patient subpopulations that will deliver the highest incremental share and long-term adherence benefits. Move beyond a KOL-only model: create tiered target lists—Tier 1 (high-volume cardiologists/cath labs and endocrine centers), Tier 2 (internists in multi-specialty clinics and diabetes centers), Tier 3 (community clinics, private GP networks) —with bespoke engagement plans.

Use claims and EMR data where available, plus hospital pharmacy dispensation trends, to identify “untapped” diabetic high-risk cohorts and clinicians treating mixed CV/diabetes caseloads. Targeting must include payer accounts (private insurers, large employers, government purchasing units) that set formularies across provider networks. For patient-level targeting, work with large diabetes clinics and national registries to identify eligible cohorts and then deploy support interventions (education, nurse-led initiation, adherence reminders). Prioritize facilities where simple operational changes (e.g., standing orders in cath labs, checklists in diabetes clinics) can materially increase identification and initiation. Regularly refresh targeting with quarterly data reviews and focus resources on the fastest-converting segments to arrest share loss and expand reach.

Account-based Management

Adopt an account-based management (ABM) model for top hospital groups, insurers, and integrated health systems to defend and grow share where volume and influence converge. For each target account, build a multidisciplinary account team combining commercial, medical affairs, market access, and local regulatory.

Develop bespoke value dossiers focused on the account’s priorities—clinical pathways for vulnerable diabetic cohorts, anticipated reductions in recurrent events, adherence benefits that reduce clinic burden, and a local RWE plan. Use account-specific KPIs (new initiations, persistency, formulary tier movement, hospital protocol adoption) and a quarterly cadence for executive-level reviews. Leverage ABM to negotiate differentiated access models (e.g., outcomes-based contracting, tiered pricing tied to adherence thresholds) and pilot initiatives that showcase operational simplicity (single-dose administration workflows, nurse support). ABM in the Gulf must account for centralized procurement and influential health authorities: include payer/government liaison as part of the account team to accelerate formulary inclusion. Intensify practitioner-level ABM within accounts by mapping key influencers (interventional cardiologists, diabetes clinic leads, pharmacy directors) and designing micro-campaigns—case conferences, simplified clinical checklists, and shared dashboards—tailored to their immediate needs.

Market Research

Commission focused market research combining quantitative claims/dispensing data, physician surveys, and qualitative ethnographic interviews to uncover actionable drivers of competitor adoption and barriers to wider use of your product. In the GCC, research must capture multi-stakeholder views: cardiologists (including cath lab), endocrinologists, internists, pharmacists, hospital formulary committees, and payers.

Key areas: reasons for competitor preference (messaging, access, samples, pricing), operational barriers to initiation (injection handling, clinic capacity), and perception gaps about label flexibility for primary prevention. Validate and culturally adapt cardiovascular risk tools via clinician workshops to design simplified local screening prompts that resonate with GCC practice patterns. Use patient research—adherence barriers for injectables, caregiver roles, language preferences—to guide patient support program design. Rapid-turnaround “pulse” surveys (every 3–4 months) will track shifts in sentiment post-campaigns. Make research outputs directly usable: prioritized list of 3–5 tactical changes, tested HCP message scripts, and a payer-focused value model with local cost inputs to inform pricing and market access negotiations.

Competitive Assessment

Conduct a granular competitor assessment focused on the competitor’s access footprint, messaging playbook, field force allocation, and real-world evidence program in the GCC. Map share by channel (public hospitals, private hospitals, outpatient clinics) and by specialty to identify bleeding points and pockets of opportunity.

Analyze competitor promotional tactics that drove rapid adoption: which specialties they targeted first, how they positioned adherence and simplicity, sample distribution and cath-lab initiatives, and any payer contracting strategies used. Translate findings into defensive and offensive moves: counter-messaging that stresses unique clinical benefits plus operational simplicity; closing the field force gap via targeted redeployment and high-impact digital detailing; and accelerating local RWE generation that addresses the competitor’s real-world claims. Track competitor tender wins, formulary placements, and any outcomes-based agreements to pre-empt similar moves with your payers. Use a quarterly competitive intelligence dossier to inform rapid adjustments in messaging, targeting, and access tactics.

Pricing Strategy

In the Gulf, pricing is a commercial as well as an access lever; align pricing strategy to demonstrate budget impact, enable formulary placement, and support broader use beyond acute/high-risk pockets. Build a payer-facing pharmacoeconomic model showing short-term budget impact and medium-term avoidance of costly cardiovascular events, incorporating local cost inputs (hospitalization, revascularization, dialysis for diabetic patients) and adherence differentials.

Consider tiered pricing or indication-based pricing to enable early access for primary prevention cohorts while protecting margins in specialty channels. Explore simple risk-sharing or outcomes-linked agreements with major public hospitals or insurers tied to initiation and 6–12 month persistence metrics—metrics that your patient support program can influence. Ensure commercial offers are operationally simple to implement (clear contract terms, measurable outcomes, manageable data-sharing requirements) and compliant with local regulations. Use pricing moves strategically: selective discounts or bundled service offers (training + starter packs + adherence support) in priority accounts where the competitor’s early access created inertia.

Customer Journey

Map and simplify the customer journey for both prescribers and patients, reducing friction points that impede initiation and adherence. For clinicians, create a one-page clinical pathway from patient identification (risk flags in diabetes clinics or cath lab referral) to initiation, follow-up, and refill—integrate into hospital workflows and EMRs where possible.

Provide quick-start toolkits (order sets, nursing checklists, injection training videos in Arabic/English) to minimize perceived complexity. For patients, design a culturally appropriate onboarding and support pathway: nurse-led initiation, bilingual digital reminders, caregiver engagement, and easy access to replacement pens and training. Monitor micro-metrics across the journey—time from identification to first dose, proportion receiving nurse education, 3/6-month persistence, and reasons for discontinuation—to optimize interventions. Use digital touchpoints (telehealth follow-up, SMS reminders, WhatsApp support where compliant) to extend reach with limited field reps. Align journey improvements to payer requirements so enhanced adherence data feeds back into market access cases.

Sales Force

Rebalance sales force deployment and capability to arrest share loss: increase presence in endocrinology and internist channels while preserving influence in cardiology/cath labs. Train reps to deliver two value scripts—one concise, practice-centered pitch emphasizing simplicity and adherence for generalists; another data-rich discussion for specialists.

Equip reps with digital tools (CRM dashboards, short video demos, one-click formulary request templates) to maximize time with HCPs. Shift to a hybrid model: targeted face-to-face for high-impact accounts, and remote detailing/webinars for broader reach. Strengthen cross-functional pairing—commercial reps with medical science liaisons—to handle complex questions without losing simplicity of message. Adjust incentive metrics away from volume-only to include initiation in new segments, support for formulary changes, and facilitation of patient onboarding. Given lower field force allocation historically, prioritize redeployment to high-conversion sites and ABM accounts and use localized scripts that address Gulf-specific workflows and payer drivers.

Value Proposition

Reframe the value proposition to combine your drug’s clinical superiority with simplicity and adherence benefits that matter to the Gulf practice environment. The core message should link rapid LDL-c reduction and robust evidence to practical outcomes: fewer clinic visits, easier dosing, and improved long-term risk reduction—packaged in a “how-to” format for clinicians.

Develop variant propositions: a payer-facing health-economic value proposition (cost avoidance, hospital readmission reductions), a specialist-facing clinical excellence proposition (efficacy and RWE evidence), and a generalist-facing practical proposition (patient identification aids, injection simplicity, low monitoring burden). Localize value claims with Gulf-specific data points (diabetes prevalence, hospitalization costs) and build a short compendium of real-world case studies from local centers showcasing operational simplicity and adherence. Position patient support programs as part of the value package—demonstrable adherence gains that underpin payer negotiations and clinician confidence.